---
http_interactions:
- request:
    method: post
    uri: https://sciencewirerest.discoverylogic.com/PublicationCatalog/PublicationQuery?format=xml
    body:
      encoding: US-ASCII
      string: ! "<?xml version=\"1.0\"?>\n      <ScienceWireQueryXMLParameter xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\"
        xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\">\n      <xmlQuery><![CDATA[\n\t
        \    <query xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:xsd=\"http://www.w3.org/2001/\n\t
        \   XMLSchema\">\n\t      <Criterion ConjunctionOperator=\"AND\">\n\t        <Criteria><Criterion>\n\t
        \           <Filter>\n\t              <Column>Title</Column>\n\t              <Operator>Contains</Operator>\n\t
        \             <Value>lung cancer treatment</Value>\n\t            </Filter>\n\t
        \         </Criterion></Criteria>\n\t      </Criterion>\n\t      <Columns>\n\t
        \       <SortColumn>\n\t          <Column>Rank</Column>\n\t          <Direction>Descending</Direction>\n\t
        \       </SortColumn>\n\t      </Columns>\n\t     <MaximumRows>20</MaximumRows>\n\t
        \   </query>\n\t    ]]></xmlQuery>\n      </ScienceWireQueryXMLParameter>"
    headers:
      Accept:
      - ! '*/*'
      User-Agent:
      - Ruby
      Licenseid:
      - ***REMOVED***
      Host:
      - sciencewirerest.discoverylogic.com
      Connection:
      - Keep-Alive
      Expect:
      - 100-continue
      Content-Type:
      - text/xml
  response:
    status:
      code: 200
      message: OK
    headers:
      Cache-Control:
      - private
      Content-Type:
      - application/xml; charset=utf-8
      Server:
      - Microsoft-IIS/7.5
      X-Aspnetmvc-Version:
      - '2.0'
      X-Aspnet-Version:
      - 4.0.30319
      X-Powered-By:
      - ASP.NET
      Date:
      - Sat, 06 Dec 2014 02:06:43 GMT
      Content-Length:
      - '279'
    body:
      encoding: US-ASCII
      string: ! "<?xml version=\"1.0\"?>\r\n<ScienceWireQueryIDResponse xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\"
        xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\r\n  <queryID>50106</queryID>\r\n
        \ <queryResultRows>20</queryResultRows>\r\n  <totalRows>20</totalRows>\r\n</ScienceWireQueryIDResponse>"
    http_version: 
  recorded_at: Sat, 06 Dec 2014 02:06:43 GMT
- request:
    method: get
    uri: https://sciencewirerest.discoverylogic.com/PublicationCatalog/PublicationQuery/50106?format=xml&page=0&pageSize=2147483647&v=version/3
    body:
      encoding: US-ASCII
      string: ''
    headers:
      Accept:
      - ! '*/*'
      User-Agent:
      - Ruby
      Content-Type:
      - text/xml
      Licenseid:
      - ***REMOVED***
      Host:
      - sciencewirerest.discoverylogic.com
      Connection:
      - Keep-Alive
  response:
    status:
      code: 200
      message: OK
    headers:
      Cache-Control:
      - private
      Content-Type:
      - application/xml; charset=utf-8
      Server:
      - Microsoft-IIS/7.5
      X-Aspnetmvc-Version:
      - '2.0'
      X-Aspnet-Version:
      - 4.0.30319
      X-Powered-By:
      - ASP.NET
      Date:
      - Sat, 06 Dec 2014 02:06:44 GMT
      Content-Length:
      - '55788'
    body:
      encoding: US-ASCII
      string: ! "<?xml version=\"1.0\"?>\r\n<ArrayOfPublicationItem xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\"
        xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>68035832</PublicationItemID>\r\n    <Title>Development
        in lung cancer treatment - from one size fits all to personalised therapy</Title>\r\n
        \   <Abstract />\r\n    <AuthorList>Espersen,B,</AuthorList>\r\n    <AuthorCount>1</AuthorCount>\r\n
        \   <KeywordList />\r\n    <DocumentTypeList>Meeting Abstract</DocumentTypeList>\r\n
        \   <DocumentCategory>Conference Proceeding Document</DocumentCategory>\r\n
        \   <NumberOfReferences>5</NumberOfReferences>\r\n    <TimesCited>0</TimesCited>\r\n
        \   <TimesNotSelfCited>0</TimesNotSelfCited>\r\n    <PMID xsi:nil=\"true\"
        />\r\n    <WoSItemID>000343363500002</WoSItemID>\r\n    <PublicationSourceTitle>EUROPEAN
        JOURNAL OF ONCOLOGY NURSING</PublicationSourceTitle>\r\n    <Volume>18</Volume>\r\n
        \   <Pagination>S1-S1</Pagination>\r\n    <PublicationDate>2014-09-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2014</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Oncology|Nursing</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1462-3889</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\" />\r\n
        \   <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\" />\r\n
        \   <OrdinalRank>0</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\" />\r\n
        \   <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>ELSEVIER SCI LTD</CopyrightPublisher>\r\n    <CopyrightCity>OXFORD</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>1.794,2013,ClosestToPublicationYear|1.794,2013,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>148/203;ONCOLOGY;2013;SC;ClosestToPublicationYear|13/107;NURSING;2013;SC;ClosestToPublicationYear|12/105;NURSING;2013;SS;ClosestToPublicationYear|148/203;ONCOLOGY;2013;SC;MostRecentYear|13/107;NURSING;2013;SC;MostRecentYear|12/105;NURSING;2013;SS;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0</AuthorCitationCountList>\r\n    <CopyrightStateProvince>OXON</CopyrightStateProvince>\r\n
        \   <CopyrightCountry>UNITED KINGDOM</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>67955507</PublicationItemID>\r\n
        \   <Title>SMALL CELL LUNG CANCER IN DAILY PRACTICE; SCOT REGISTRY (SMALL
        CELL LUNG CANCER TREATMENT AND OUTCOME)</Title>\r\n    <Abstract />\r\n    <AuthorList>Postmus,Pieter,E|Quoix,Elisabeth,|Ardizzioni,Andrea,|Le
        Chevalier,Thierry,|Garrido,Pilar,|Raillard,Alice,|Rabier,Paola,|Lavigne,Stephane,|Deville,Coralie,|Fletcher,Joanne,|Sapunar,Francisco,|Mehmud,Faisal,</AuthorList>\r\n
        \   <AuthorCount>12</AuthorCount>\r\n    <KeywordList>small cell lung cancer|chemoradiotherapy|Platinum/Etoposide</KeywordList>\r\n
        \   <DocumentTypeList>Meeting Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference
        Proceeding Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\"
        />\r\n    <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000339624901203</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF THORACIC ONCOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>8</Volume>\r\n    <Pagination>S339-S339</Pagination>\r\n    <PublicationDate>2013-11-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2013</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Oncology|Respiratory System</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1556-0864</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\" />\r\n
        \   <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\" />\r\n
        \   <OrdinalRank>1</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\" />\r\n
        \   <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>LIPPINCOTT WILLIAMS &amp; WILKINS</CopyrightPublisher>\r\n
        \   <CopyrightCity>PHILADELPHIA</CopyrightCity>\r\n    <PublicationImpactFactorList>4.473,2012,ClosestToPublicationYear|4.473,2012,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>42/197;ONCOLOGY;2012;SC;ClosestToPublicationYear|6/50;RESPIRATORY
        SYSTEM;2012;SC;ClosestToPublicationYear|42/197;ONCOLOGY;2012;SC;MostRecentYear|6/50;RESPIRATORY
        SYSTEM;2012;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0|9,0,0|10,0,0|11,0,0|12,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>PA</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>67917818</PublicationItemID>\r\n    <Title>A PHASE
        II STUDY OF CISPLATIN AND ORAL VINORELBINE CONCOMITANTLY WITH RADIOTHERAPY
        IN LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER TREATMENT: EFICACY AND SAFETY
        RESULTS.</Title>\r\n    <Abstract />\r\n    <AuthorList>Juan,Oscar,|Vazquez,Sergio,|Garcia,Jose,|Luis
        Firvida,Jose,|Aparisi,Francisco,|Munoz,Jose,|Casal,Joaquin,|Giner,Vicente,|Girones,Regina,|Lazaro,Martin,|Garde,Javier,|Sanchez-Hernandez,Alfredo,</AuthorList>\r\n
        \   <AuthorCount>12</AuthorCount>\r\n    <KeywordList>cisplatin|vinorelbine|non-small-cell
        lung cancer|radiotherapy</KeywordList>\r\n    <DocumentTypeList>Meeting Abstract</DocumentTypeList>\r\n
        \   <DocumentCategory>Conference Proceeding Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited>0</TimesCited>\r\n
        \   <TimesNotSelfCited>0</TimesNotSelfCited>\r\n    <PMID xsi:nil=\"true\"
        />\r\n    <WoSItemID>000339624905272</WoSItemID>\r\n    <PublicationSourceTitle>JOURNAL
        OF THORACIC ONCOLOGY</PublicationSourceTitle>\r\n    <Volume>8</Volume>\r\n
        \   <Pagination>S1153-S1154</Pagination>\r\n    <PublicationDate>2013-11-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2013</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Oncology|Respiratory System</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1556-0864</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\" />\r\n
        \   <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\" />\r\n
        \   <OrdinalRank>2</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\" />\r\n
        \   <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>LIPPINCOTT WILLIAMS &amp; WILKINS</CopyrightPublisher>\r\n
        \   <CopyrightCity>PHILADELPHIA</CopyrightCity>\r\n    <PublicationImpactFactorList>4.473,2012,ClosestToPublicationYear|4.473,2012,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>42/197;ONCOLOGY;2012;SC;ClosestToPublicationYear|6/50;RESPIRATORY
        SYSTEM;2012;SC;ClosestToPublicationYear|42/197;ONCOLOGY;2012;SC;MostRecentYear|6/50;RESPIRATORY
        SYSTEM;2012;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0|9,0,0|10,0,0|11,0,0|12,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>PA</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>67806067</PublicationItemID>\r\n    <Title>THE COSTS
        AND REIMBURSEMENTS FOR LUNG CANCER TREATMENT AMONG SELECTED HEALTH CARE PROVIDERS
        IN THE CZECH REPUBLIC</Title>\r\n    <Abstract>The objective of the article
        is to objectivise and assess the costs for the lung cancer therapy from the
        payer's (health insurance company) and the healthcare provider's (hospital)
        perspective based on information available from several large hospitals and
        specialised centres. No comprehensive assessment of costs related to the treatment
        of lung cancers at all stages has been published in the Czech Republic to-date.
        The results in this study are calculated based on diagnostic and therapeutic
        algorithms, i.e. process maps. These, in turn, are derived from the recommended
        therapeutic procedures issued by the Masaryk Institute of Oncology, the University
        Hospital in Hradec Kralove and the University Hospital in Plzen. In total,
        the costs and reimbursements were calculated for 32 utilized algorithms, i.e.
        process maps. The costs for therapeutic processes account for 22 results,
        while 10 results correspond to diagnostic processes. Both direct and indirect
        costs were included in individual calculations. The calculations imply that
        treatment costs significantly differ depending on the selected diagnostic
        and therapeutic procedure. It becomes apparent that the setting of the reimbursement
        system presently generates different stimuli for providers, who may reach
        both positive and negative balances. This fact, in turn, may have an effect
        on the economic result leading, in its consequence, to the preference of more
        suitable alternatives in terms of reimbursement regardless of the optimum
        procedures for the particular patient. This fact is, to a certain extent,
        reflected by the reimbursements calculated by means of the DRG system. The
        given algorithms may potentially be used by health care providers to reach
        working costs, which will allow accurate calculations for particular hospitals.</Abstract>\r\n
        \   <AuthorList>Simrova,Jana,|Bartak,Miroslav,|Vojtisek,Radovan,|Rogalewicz,Vladimir,</AuthorList>\r\n
        \   <AuthorCount>4</AuthorCount>\r\n    <KeywordList>UNITED-KINGDOM|NETHERLANDS|MANAGEMENT|GERMANY|FRANCE|healthcare
        costs|lung cancer|Process Maps|health care reimbursement</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>31</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000342261200007</WoSItemID>\r\n
        \   <PublicationSourceTitle>E &amp; M EKONOMIE A MANAGEMENT</PublicationSourceTitle>\r\n
        \   <Volume>17</Volume>\r\n    <Issue>3</Issue>\r\n    <Pagination>74-85</Pagination>\r\n
        \   <PublicationDate>2014-01-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2014</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Economics|Management</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1212-3609</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\" />\r\n
        \   <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\" />\r\n
        \   <OrdinalRank>3</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\" />\r\n
        \   <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>TECHNICKA UNIV &amp; LIBERCI</CopyrightPublisher>\r\n
        \   <CopyrightCity>LIBEREC 1</CopyrightCity>\r\n    <PublicationImpactFactorList>0.633,2012,ClosestToPublicationYear|0.633,2012,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>200/333;ECONOMICS;2012;SS;ClosestToPublicationYear|131/174;MANAGEMENT;2012;SS;ClosestToPublicationYear|200/333;ECONOMICS;2012;SS;MostRecentYear|131/174;MANAGEMENT;2012;SS;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>CZECH REPUBLIC</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>67795320</PublicationItemID>\r\n
        \   <Title>Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment:
        Potential for Aerosol Delivery</Title>\r\n    <Abstract>Paclitaxel (PTX, Taxol)
        has revolutionized cancer treatment in the past decade and is recognized as
        one of the biggest advances in oncology medicine. In spite of the good clinical
        efficacy shown by PTX, there is still a growing need to achieve better safety
        and pharmacokinetic profile of PTX in patients. The standard delivery modalities
        of intravenous infusion result in multiple side effects, and targeting of
        the drug to specific areas within the body can result in better efficacy and
        lower toxicity. Aerosol delivery of therapeutic agents has the potential of
        localizing the drugs specifically to the lung tissue, with a comparable or
        better pharmacokinetics as compared to intravenous, oral or intraperitoneal
        delivery. Aerosol delivery of PTX has not been studied extensively, however,
        it holds immense potential for improving the efficacy against lung tumors.
        Early pre-clinical studies in mice and dogs have shown good promise, both
        for pharmacokinetics of PTX, safety and efficacy in lung cancer models. This
        review looks at the still developing approach of aerosol delivery of PTX for
        lung cancer, documents the progress so far and the future directions that
        can bring this approach to clinical reality.</Abstract>\r\n    <AuthorList>Gautam,Ajay,|Koshkina,Nadezhda,</AuthorList>\r\n
        \   <AuthorCount>2</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>62</NumberOfReferences>\r\n
        \   <TimesCited>23</TimesCited>\r\n    <TimesNotSelfCited>23</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000209053000006</WoSItemID>\r\n
        \   <PublicationSourceTitle>CURRENT CANCER DRUG TARGETS</PublicationSourceTitle>\r\n
        \   <Volume>3</Volume>\r\n    <Issue>4</Issue>\r\n    <Pagination>287-296</Pagination>\r\n
        \   <PublicationDate>2003-01-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2003</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1568-0096</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\" />\r\n
        \   <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\" />\r\n
        \   <OrdinalRank>4</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\" />\r\n
        \   <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>BENTHAM SCIENCE PUBL LTD</CopyrightPublisher>\r\n
        \   <CopyrightCity>SHARJAH</CopyrightCity>\r\n    <PublicationImpactFactorList>5.677,2006,ClosestToPublicationYear|4,2012,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>17/127;ONCOLOGY;2006;SC;ClosestToPublicationYear|54/197;ONCOLOGY;2012;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,23|2,0,23</AuthorCitationCountList>\r\n    <CopyrightStateProvince
        />\r\n    <CopyrightCountry>U ARAB EMIRATES</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>67709259</PublicationItemID>\r\n
        \   <Title>COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN COMBINATION WITH
        PC REGIMEN VERSUS PC REGIMEN IN NON-SMALL CELL LUNG CANCER TREATMENT</Title>\r\n
        \   <Abstract />\r\n    <AuthorList>Nguyen,T,TT|Tran,T,TH</AuthorList>\r\n
        \   <AuthorCount>2</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Meeting
        Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference Proceeding
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000341082000473</WoSItemID>\r\n
        \   <PublicationSourceTitle>VALUE IN HEALTH</PublicationSourceTitle>\r\n    <Volume>17</Volume>\r\n
        \   <Issue>3</Issue>\r\n    <Pagination>A87-A87</Pagination>\r\n    <PublicationDate>2014-05-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2014</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Economics|Health Care Sciences &amp; Services|Health
        Policy &amp; Services</PublicationSubjectCategoryList>\r\n    <ISSN>1098-3015</ISSN>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>5</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>ELSEVIER
        SCIENCE INC</CopyrightPublisher>\r\n    <CopyrightCity>NEW YORK</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>2.191,2012,ClosestToPublicationYear|2.191,2012,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>26/83;HEALTH CARE SCIENCES &amp; SERVICES;2012;SC;ClosestToPublicationYear|16/67;HEALTH
        POLICY &amp; SERVICES;2012;SS;ClosestToPublicationYear|36/333;ECONOMICS;2012;SS;ClosestToPublicationYear|26/83;HEALTH
        CARE SCIENCES &amp; SERVICES;2012;SC;MostRecentYear|16/67;HEALTH POLICY &amp;
        SERVICES;2012;SS;MostRecentYear|36/333;ECONOMICS;2012;SS;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0</AuthorCitationCountList>\r\n    <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n
        \   <CopyrightCountry>UNITED STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>67681489</PublicationItemID>\r\n
        \   <Title>A REVELation in non-small-cell lung cancer treatment?</Title>\r\n
        \   <Abstract />\r\n    <AuthorList>Mok,Tony,SK|Loong,Herbert,H</AuthorList>\r\n
        \   <AuthorCount>2</AuthorCount>\r\n    <KeywordList>COMBINATION|DOCETAXEL|ENDOTHELIAL
        GROWTH-FACTOR|CHEMOTHERAPY|BEVACIZUMAB|CARBOPLATIN|MUTATIONS|PHASE-III|TRIAL</KeywordList>\r\n
        \   <DocumentTypeList>Editorial Material</DocumentTypeList>\r\n    <DocumentCategory>Other</DocumentCategory>\r\n
        \   <NumberOfReferences>12</NumberOfReferences>\r\n    <TimesCited>0</TimesCited>\r\n
        \   <TimesNotSelfCited>0</TimesNotSelfCited>\r\n    <PMID>24933331</PMID>\r\n
        \   <WoSItemID>000341359100007</WoSItemID>\r\n    <PublicationSourceTitle>LANCET</PublicationSourceTitle>\r\n
        \   <Volume>384</Volume>\r\n    <Issue>9944</Issue>\r\n    <Pagination>640-642</Pagination>\r\n
        \   <PublicationDate>2014-08-23T00:00:00</PublicationDate>\r\n    <PublicationYear>2014</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Medicine,
        General &amp; Internal</PublicationSubjectCategoryList>\r\n    <ISSN>0140-6736</ISSN>\r\n
        \   <DOI>10.1016/S0140-6736(14)60895-3</DOI>\r\n    <ConferenceStartDate xsi:nil=\"true\"
        />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\"
        />\r\n    <OrdinalRank>6</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\"
        />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>ELSEVIER SCIENCE INC</CopyrightPublisher>\r\n    <CopyrightCity>NEW
        YORK</CopyrightCity>\r\n    <PublicationImpactFactorList>39.06,2012,ClosestToPublicationYear|39.06,2012,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>2/155;MEDICINE, GENERAL &amp; INTERNAL;2012;SC;ClosestToPublicationYear|2/155;MEDICINE,
        GENERAL &amp; INTERNAL;2012;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0</AuthorCitationCountList>\r\n    <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n
        \   <CopyrightCountry>UNITED STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>67666958</PublicationItemID>\r\n
        \   <Title>[Lung cancer: progress in diagnosis and treatments. Topics: III.
        Treatment; 7. Lung cancer treatment in elderly and/or high risk patients].</Title>\r\n
        \   <Abstract />\r\n    <AuthorList>Kimura,Tastuo,|Kudoh,Shinzoh,|Hirata,Kazuto,</AuthorList>\r\n
        \   <AuthorCount>3</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Journal
        Article</DocumentTypeList>\r\n    <DocumentCategory>Journal Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\"
        />\r\n    <TimesNotSelfCited xsi:nil=\"true\" />\r\n    <PMID>25151800</PMID>\r\n
        \   <PublicationSourceTitle>Nihon Naika Gakkai zasshi. The Journal of the
        Japanese Society of Internal Medicine</PublicationSourceTitle>\r\n    <Volume>103</Volume>\r\n
        \   <Issue>6</Issue>\r\n    <Pagination>1346-1354</Pagination>\r\n    <PublicationDate>2014-06-10T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2014</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>0021-5384</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\"
        />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\"
        />\r\n    <OrdinalRank>7</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\"
        />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher />\r\n    <CopyrightCity />\r\n    <CopyrightStateProvince
        />\r\n    <CopyrightCountry>JAPAN</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>67578852</PublicationItemID>\r\n
        \   <Title>Pulmonary Multifunctional Nano-Oncological Modules for Lung Cancer
        Treatment and Prevention</Title>\r\n    <Abstract>Mortality associated with
        lung cancer and its metastasis has outnumbered those related to other forms
        of cancer. Despite being a directly accessible organ, conventional oncological
        strategies exhibiting prolific outcome in treatment and prevention of lung
        cancer is far from reality. This is attributed to numerous challenges posed
        by lung environment. The extracellular aura of lung comprises immensely complicated
        structures, ciliary escalators, omnipresence of mucus and alveolar fluid,
        and macrophagial uptake which presents an array of impediments to the arrival
        of therapeutic moiety at the tumor site. Besides these, intracellular obstacles
        viz enzymatic degradation, cell membrane translocation, endosomal escape and/or
        nuclear entry also limit superior therapeutic efficacy. The current review
        elaborates wide-ranging challenges to lung cancer treatment and its circumvention
        by latest developments in multifunctional nano-oncological modules delivered
        via the pulmonary route-which smartly deal with the abovementioned issues
        and bestow positivity to this complication.</Abstract>\r\n    <AuthorList>Shete,Harshad,K|Vyas,Swati,S|Patravale,Vandana,B|Disouza,John,I</AuthorList>\r\n
        \   <AuthorCount>4</AuthorCount>\r\n    <KeywordList>FUNCTIONALIZED GOLD NANOPARTICLES|DRUG-DELIVERY|SMALL
        INTERFERING RNA|WALL CARBON NANOHORNS|CELLS IN-VITRO|IRON-OXIDE NANOPARTICLES|HUMAN-TUMOR
        XENOGRAFTS|MOLONEY LEUKEMIA-VIRUS|MESOPOROUS SILICA NANOPARTICLE|NANOSTRUCTURED
        LIPID CARRIERS|pulmonary delivery|lung cancer|nanoparticles|metastasis|Nano-Oncological
        Modules</KeywordList>\r\n    <DocumentTypeList>Review</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>276</NumberOfReferences>\r\n
        \   <TimesCited>1</TimesCited>\r\n    <TimesNotSelfCited>1</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000339430600010</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF BIOMEDICAL NANOTECHNOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>10</Volume>\r\n    <Issue>9</Issue>\r\n    <Pagination>1863-1893</Pagination>\r\n
        \   <PublicationDate>2014-09-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2014</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Nanoscience
        &amp; Nanotechnology|Materials Science, Biomaterials</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1550-7033</ISSN>\r\n    <DOI>10.1166/jbn.2014.1900</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>8</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>AMER SCIENTIFIC PUBLISHERS</CopyrightPublisher>\r\n
        \   <CopyrightCity>VALENCIA</CopyrightCity>\r\n    <PublicationImpactFactorList>5.256,2012,ClosestToPublicationYear|5.256,2012,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>17/69;NANOSCIENCE &amp; NANOTECHNOLOGY;2012;SC;ClosestToPublicationYear|16/121;MEDICINE,
        RESEARCH &amp; EXPERIMENTAL;2012;SC;ClosestToPublicationYear|17/69;NANOSCIENCE
        &amp; NANOTECHNOLOGY;2012;SC;MostRecentYear|16/121;MEDICINE, RESEARCH &amp;
        EXPERIMENTAL;2012;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,1|2,0,1|3,0,1|4,0,1</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>CA</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>67547749</PublicationItemID>\r\n    <Title>Association
        of Patient-Provider Communication Domains with Lung Cancer Treatment</Title>\r\n
        \   <Abstract>Background: Patient-physician communication is critical for
        helping patients understand and complete the complex steps needed to diagnose
        stage and treat lung cancer. We assessed which domains of patient-physician
        communication about lung cancer and its treatment are associated with receipt
        of disease-directed, stage-appropriate treatment.  Methods: Patients with
        recently diagnosed lung cancer were recruited from four medical centers in
        New York City from 2008 to 2011. Participants were surveyed about discussions
        with physicians regarding treatment, symptoms, and needs. Multiple regression
        analysis and structural equation modeling were used to assess which communication
        factors were associated with disease treatment.  Results: Of the 352 participants,
        191 (54%) received disease-directed, stage-appropriate treatment. Unadjusted
        associations between communication items and treatment found that participants
        who felt that their physicians explained the risks and disadvantages of lung
        cancer treatment (p &lt; 0.01), discussed their chances of cure (p = 0.02),
        discussed goals of treatment (p &lt; 0.01), or who were warm and friendly
        (p = 0.04) were more likely to undergo treatment. Three communication domains
        were identified: treatment information, physician support, and patient symptoms/needs.
        After adjusting for known determinants of lung cancer treatment, increased
        treatment information was associated with higher probability of cancer-directed
        treatment (p = 0.003). Other communication domains (physician support or patient
        symptoms/needs) were not independent predictors of treatment (p &gt; 0.05
        for both comparisons).  Conclusion: These data suggest that treatment information
        is particularly important for increasing the probability of cancer-directed
        therapy among lung cancer patients. Clinicians should ensure that they clearly
        discuss treatment goals and options with patients while maintaining empathy,
        supporting patient needs, and addressing symptoms.</Abstract>\r\n    <AuthorList>Lin,Jenny,J|Lake,Jessica,|Wall,Melanie,M|Berman,Andrew,R|Salazar-Schicchi,John,|Powell,Charles,|Keller,Steven,M|Halm,Ethan,A|Leventhal,Howard,|Wisnivesky,Juan,P</AuthorList>\r\n
        \   <AuthorCount>10</AuthorCount>\r\n    <KeywordList>MEDICAL CONSULTATIONS|SOCIAL
        SUPPORT|POPULATION|SATISFACTION|PHYSICIAN COMMUNICATION|BREAST-CANCER|ADHERENCE|CHEMOTHERAPY|HEALTH
        OUTCOMES|INFORMATION|lung cancer|patient-provider communication|treatment</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>37</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>25122421</PMID>\r\n    <WoSItemID>000341025800009</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF THORACIC ONCOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>9</Volume>\r\n    <Issue>9</Issue>\r\n    <Pagination>1249-1254</Pagination>\r\n
        \   <PublicationDate>2014-09-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2014</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology|Respiratory
        System</PublicationSubjectCategoryList>\r\n    <ISSN>1556-0864</ISSN>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>9</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>LIPPINCOTT
        WILLIAMS &amp; WILKINS</CopyrightPublisher>\r\n    <CopyrightCity>PHILADELPHIA</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>4.473,2012,ClosestToPublicationYear|4.473,2012,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>42/197;ONCOLOGY;2012;SC;ClosestToPublicationYear|6/50;RESPIRATORY
        SYSTEM;2012;SC;ClosestToPublicationYear|42/197;ONCOLOGY;2012;SC;MostRecentYear|6/50;RESPIRATORY
        SYSTEM;2012;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0|9,0,0|10,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>PA</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>67407985</PublicationItemID>\r\n    <Title>The role
        of patient, tumour and system factors in socioeconomic inequalities in lung
        cancer treatment: population-based study</Title>\r\n    <Abstract>Background:
        Reducing socioeconomic inequalities in lung cancer treatment may reduce survival
        inequalities. However, the reasons for treatment variation are unclear.  Methods:
        Northern and Yorkshire cancer registry, Hospital Episode Statistics and lung
        cancer audit data sets were linked. Logistic regression was used to explore
        the role of stage, histology, performance status and comorbidity in socioeconomic
        inequalities in lung cancer treatment, for 28 733 lung cancer patients diagnosed
        in 2006-2010, and in a subgroup with stage recorded (n = 7769, 27%).  Results:
        Likelihood of receiving surgery was significantly lower in the most deprived
        group (odds ratio (OR) = 0.75, 95% confidence interval (CI) 0.65-0.86); however,
        the OR was attenuated when including histological subtype (OR = 0.82, 95%
        CI 0.71-0.96). Patients in the most deprived group were significantly less
        likely to receive chemotherapy in the fully adjusted full cohort model including
        performance status (OR = 0.64, 95% CI 0.58-0.72) but not in the staged subgroup
        model when performance status was included (OR = 0.88, 95% CI 0.72-1.08).
        Socioeconomic inequalities in radiotherapy were not found.  Interpretation:
        Socioeconomic inequalities in performance status statistically explained socioeconomic
        inequalities in receipt of chemotherapy in the selective staged subgroup,
        but not in the full cohort. Socioeconomic variation in histological subtype
        may account for some of the socioeconomic inequalities in surgery.</Abstract>\r\n
        \   <AuthorList>Forrest,L,F|White,M,|Rubin,G,|Adams,J,</AuthorList>\r\n    <AuthorCount>4</AuthorCount>\r\n
        \   <KeywordList>ENGLAND|SURVIVAL|COMORBIDITY|AGE|UK|SUBTYPE|surgery|lung
        cancer|treatment|chemotherapy|socioeconomic position|radiotherapy</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>35</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>24918815</PMID>\r\n    <WoSItemID>000340205400025</WoSItemID>\r\n
        \   <PublicationSourceTitle>BRITISH JOURNAL OF CANCER</PublicationSourceTitle>\r\n
        \   <Volume>111</Volume>\r\n    <Issue>3</Issue>\r\n    <Pagination>608-618</Pagination>\r\n
        \   <PublicationDate>2014-07-29T00:00:00</PublicationDate>\r\n    <PublicationYear>2014</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0007-0920</ISSN>\r\n    <DOI>10.1038/bjc.2014.310</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>10</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>NATURE PUBLISHING GROUP</CopyrightPublisher>\r\n    <CopyrightCity>LONDON</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>5.082,2012,ClosestToPublicationYear|5.082,2012,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>35/197;ONCOLOGY;2012;SC;ClosestToPublicationYear|35/197;ONCOLOGY;2012;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED KINGDOM</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>67375959</PublicationItemID>\r\n
        \   <Title>Non-small Cell Lung Cancer Treatment Receipt and Survival Among
        African-Americans and Whites in a Rural Area</Title>\r\n    <Abstract>Data
        on racial disparities among lung cancer patients in rural areas are scarce.
        We examined differences in treatment receipt and survival among African-American
        (AA) and Non-Hispanic White (NHW) non-small cell lung cancer (NSCLC) patients
        residing in Southwest Georgia (SWGA)-a primarily rural 33-county area; population
        700,000. Medical records for 934 SWGA NSCLC patients diagnosed in 2001-2003
        were used to extract information on age, race, marital status, insurance coverage,
        comorbidities, and treatment. Information pertaining to socioeconomic status,
        urban/rural residence, and survival was obtained from the cancer registry.
        Multivariable logistic regression analyses examined the relation of various
        patient and disease characteristics to receipt of tumor-directed therapy.
        Cox regression models were used to assess determinants of survival. Treatment
        receipt was associated with age, marital status, comorbidities, and disease
        stage in most analyses. No associations were observed between race and either
        surgery [odds ratio (OR) 0.83, 95 % confidence interval (CI) 0.49-1.39] or
        radiation (OR 0.72; 95 % CI 0.52-1.00). NHW patients were more likely to receive
        no treatment at all (OR 1.50, 95 % CI 1.01-2.23). There was no racial difference
        in survival (hazard ratio = 1.07, 95 % CI 0.90-1.26). Effects of insurance
        and treatment on survival were most pronounced within 6 months post-diagnosis,
        but were attenuated over time. We found no evidence of racial disparities
        in survival and, in some analyses, a decreased likelihood of treatment receipt
        among NHW NSCLC patients compared to AA. The results from SWGA stand in contrast
        to studies that applied different methodologies and were conducted elsewhere.</Abstract>\r\n
        \   <AuthorList>Hua,Xinwei,|Ward,Kevin,C|Gillespie,Theresa,W|Lipscomb,Joseph,|Goodman,Michael,</AuthorList>\r\n
        \   <AuthorCount>5</AuthorCount>\r\n    <KeywordList>MEDICAL-RECORD|HEALTH|SMOKING|COMORBIDITY|DISPARITIES|SOCIOECONOMIC-STATUS|WATER|SANITATION|RACE|OUTCOMES|racial
        disparities|prognosis|lung cancer|rural residence|treatment receipt</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>33</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>24346819</PMID>\r\n    <WoSItemID>000338539800009</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF COMMUNITY HEALTH</PublicationSourceTitle>\r\n
        \   <Volume>39</Volume>\r\n    <Issue>4</Issue>\r\n    <Pagination>696-705</Pagination>\r\n
        \   <PublicationDate>2014-08-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2014</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Health
        Policy &amp; Services|Public, Environmental &amp; Occupational Health</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0094-5145</ISSN>\r\n    <DOI>10.1007/s10900-013-9813-7</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>11</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>SPRINGER</CopyrightPublisher>\r\n
        \   <CopyrightCity>NEW YORK</CopyrightCity>\r\n    <PublicationImpactFactorList>1.293,2012,ClosestToPublicationYear|1.293,2012,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>44/67;HEALTH POLICY &amp; SERVICES;2012;SS;ClosestToPublicationYear|76/139;PUBLIC,
        ENVIRONMENTAL &amp; OCCUPATIONAL HEALTH;2012;SS;ClosestToPublicationYear|44/67;HEALTH
        POLICY &amp; SERVICES;2012;SS;MostRecentYear|76/139;PUBLIC, ENVIRONMENTAL
        &amp; OCCUPATIONAL HEALTH;2012;SS;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>66227041</PublicationItemID>\r\n    <Title>Regression
        analysis of indicating multiple incremental cost-effectiveness ratios for
        non-small cell lung cancer treatment.</Title>\r\n    <Abstract>OBJECTIVES
        The value of a health technology can be measured in terms of cost and benefit
        on two-dimensional co-ordinates. This study is to quantitatively analyze the
        correlation and to conduct a regression on the X-Y plane constituted by cost
        and QALYs (quality-adjusted life years) associated with the first line treatment,
        the maintenance treatment, and the second line treatment for non-small cell
        lung cancer (NSCLC).\r\nMETHODS The cost-effectiveness data of the cost and
        QALYs were extracted, with respect to the three categories of the NSCLC treatment,
        from the CEA Registry at Tufts Medical Center, regarding the literature published
        from 2000-2011. As a result, 44 QALY-cost ratios were identified.\r\nRESULTS
        Based on those extracted data, the correlation and regression analyses were
        performed by mathematical model using log and square-root functions. The plotted
        ratios stratified by the three stages for the NSCLC treatment were visually
        grouped into three clusters. There were statistically significant differences
        among the correlation coefficients of the cluster. In regression, the log
        model was found to be better fitted than the square-root model; formulating
        QALY?=?-1.12?+?0.16 log(Cost), -1.99?+?0.28 log(Cost), and -0.69?+?0.10 log(Cost)
        for the first line, the maintenance, and the second line treatment, respectively.
        Monetary units were standardized to 2008 US dollars.\r\nCONCLUSION A good
        methodological potential was confirmed so as to assess the Incremental Cost
        Effectiveness Ratio (ICER) variations, considering stratification by multiple
        factors such as disease and treatment categories. This study has certain limitations,
        such as the small number of included articles and the stratification, not
        reflecting a factor of new genetic findings.</Abstract>\r\n    <AuthorList>Nakahara,Naohiro,|Kamae,Isao,</AuthorList>\r\n
        \   <AuthorCount>2</AuthorCount>\r\n    <KeywordList>ICER|Incremental cost
        effectiveness ratio|QALYs|Quality-adjusted life years|Regression Non-small
        cell lung cancer</KeywordList>\r\n    <DocumentTypeList>Journal Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences
        xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\" />\r\n    <TimesNotSelfCited
        xsi:nil=\"true\" />\r\n    <PMID>24826807</PMID>\r\n    <PublicationSourceTitle>Journal
        of medical economics</PublicationSourceTitle>\r\n    <Volume>17</Volume>\r\n
        \   <Issue>8</Issue>\r\n    <Pagination>547-554</Pagination>\r\n    <PublicationDate>2014-08-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2014</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>1369-6998</ISSN>\r\n    <DOI>10.3111/13696998.2014.923890</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>12</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED
        KINGDOM</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>66135060</PublicationItemID>\r\n    <Title>ICOVIR-15
        and Inducible Caspase-9 Delivered By Mesenchymal Stromal Cells (MSCs) for
        Lung Cancer Treatment</Title>\r\n    <Abstract />\r\n    <AuthorList>Hoyos,Valentina,|Yagyu,Shigeki,|Ando,Miki,|Del
        Bufalo,Francesca,|Tao,Wade,|Ramos,Carlos,|Dotti,Gianpietro,|Alemany,Ramon,|Brenner,Malcolm,K</AuthorList>\r\n
        \   <AuthorCount>9</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Meeting
        Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference Proceeding
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000337231300173</WoSItemID>\r\n
        \   <PublicationSourceTitle>MOLECULAR THERAPY</PublicationSourceTitle>\r\n
        \   <Volume>22</Volume>\r\n    <Pagination>S65-S66</Pagination>\r\n    <PublicationDate>2014-05-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2014</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Biotechnology &amp; Applied Microbiology|Genetics
        &amp; Heredity|Medicine, Research &amp; Experimental</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1525-0016</ISSN>\r\n    <ConferenceTitle>17th Annual Meeting of
        the American-Society-of-Gene-and-Cell-Therapy (ASGCT)</ConferenceTitle>\r\n
        \   <ConferenceStartDate>2014-05-21T00:00:00</ConferenceStartDate>\r\n    <ConferenceEndDate>2014-05-24T00:00:00</ConferenceEndDate>\r\n
        \   <ConferenceCity>WASHINGTON</ConferenceCity>\r\n    <ConferenceStateCountry>DC</ConferenceStateCountry>\r\n
        \   <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>13</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>NATURE PUBLISHING GROUP</CopyrightPublisher>\r\n    <CopyrightCity>NEW
        YORK</CopyrightCity>\r\n    <PublicationImpactFactorList>7.041,2012,ClosestToPublicationYear|7.041,2012,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>9/160;BIOTECHNOLOGY &amp; APPLIED MICROBIOLOGY;2012;SC;ClosestToPublicationYear|16/161;GENETICS
        &amp; HEREDITY;2012;SC;ClosestToPublicationYear|10/121;MEDICINE, RESEARCH
        &amp; EXPERIMENTAL;2012;SC;ClosestToPublicationYear|9/160;BIOTECHNOLOGY &amp;
        APPLIED MICROBIOLOGY;2012;SC;MostRecentYear|16/161;GENETICS &amp; HEREDITY;2012;SC;MostRecentYear|10/121;MEDICINE,
        RESEARCH &amp; EXPERIMENTAL;2012;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0|9,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>66103701</PublicationItemID>\r\n    <Title>Non-small-cell
        lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers.</Title>\r\n
        \   <Abstract>Systemic therapy should be considered in patients with advanced
        non-small cell lung cancer (NSCLC) who are no longer amenable to local therapies.
        Systemic therapy has been shown to improve survival and preserve quality of
        life in patients with a reasonable performance status. In unselected patients,
        the standard of care for initial therapy remains platinum-based chemotherapy.
        At progression, further treatment typically consists of the sequential administration
        of single-agent therapy, which has also been shown to improve survival and
        reduce cancer-related symptoms. Molecular biomarkers are essential to guide
        targeted agents. This analysis requires ample tumor DNA; thus adequate biopsy
        samples are critical to guide therapeutic options. More biomarkers are currently
        being validated and may potentially have specific targeted therapy. In the
        near future, it is likely that rapid multiplexed genotype testing will help
        reduce the need for large amounts of tumor for analysis and will promote personalized
        cancer therapy. We review recent changes in the definition of stage IV NSCLC
        and review current and future systemic therapeutic approaches for patients
        with advanced disease. </Abstract>\r\n    <AuthorList>Scheff,Ronald,J|Schneider,Bryan,J</AuthorList>\r\n
        \   <AuthorCount>2</AuthorCount>\r\n    <KeywordList>chemotherapy|non-small
        cell lung cancer|systemic therapy|targeted therapy</KeywordList>\r\n    <DocumentTypeList>Journal
        Article|Review</DocumentTypeList>\r\n    <DocumentCategory>Journal Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\"
        />\r\n    <TimesNotSelfCited xsi:nil=\"true\" />\r\n    <PMID>24436536</PMID>\r\n
        \   <PublicationSourceTitle>Seminars in interventional radiology</PublicationSourceTitle>\r\n
        \   <Volume>30</Volume>\r\n    <Issue>2</Issue>\r\n    <Pagination>191-198</Pagination>\r\n
        \   <PublicationDate>2013-06-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2013</PublicationYear>\r\n
        \   <PublicationSubjectCategoryList />\r\n    <ISSN>0739-9529</ISSN>\r\n    <DOI>10.1055/s-0033-1342961</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>14</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <PublicationImpactFactorList>0.16,2000,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>77/80;RADIOLOGY, NUCLEAR MEDICINE &amp;
        MEDICAL IMAGING;2000;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED STATES</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>66099926</PublicationItemID>\r\n
        \   <Title>[State of the lung cancer treatment].</Title>\r\n    <Abstract
        />\r\n    <AuthorList>Kawamura,Masafumi,</AuthorList>\r\n    <AuthorCount>1</AuthorCount>\r\n
        \   <KeywordList />\r\n    <DocumentTypeList>Introductory Journal Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Other</DocumentCategory>\r\n    <NumberOfReferences
        xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\" />\r\n    <TimesNotSelfCited
        xsi:nil=\"true\" />\r\n    <PMID>24946516</PMID>\r\n    <PublicationSourceTitle>Nihon
        Geka Gakkai zasshi</PublicationSourceTitle>\r\n    <Volume>115</Volume>\r\n
        \   <Issue>3</Issue>\r\n    <Pagination>119-?</Pagination>\r\n    <PublicationDate>2014-05-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2014</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>0301-4894</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\"
        />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\"
        />\r\n    <OrdinalRank>15</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\"
        />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher />\r\n    <CopyrightCity />\r\n    <CopyrightStateProvince
        />\r\n    <CopyrightCountry>JAPAN</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>66026815</PublicationItemID>\r\n
        \   <Title>Registration Accuracy with Four-Dimensional Cone-Beam CT for Lung
        Cancer Treatment</Title>\r\n    <Abstract />\r\n    <AuthorList>Haga,A,|Kotoku,J,|Kida,S,|Masutani,Y,|Yamashita,H,|Takahashi,W,|Imae,T,|Nakagawa,K,</AuthorList>\r\n
        \   <AuthorCount>8</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Meeting
        Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference Proceeding
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000336849902590</WoSItemID>\r\n
        \   <PublicationSourceTitle>MEDICAL PHYSICS</PublicationSourceTitle>\r\n    <Volume>40</Volume>\r\n
        \   <Issue>6</Issue>\r\n    <Pagination />\r\n    <PublicationDate>2013-06-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2013</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Radiology, Nuclear Medicine &amp; Medical
        Imaging</PublicationSubjectCategoryList>\r\n    <ISSN>0094-2405</ISSN>\r\n
        \   <DOI>10.1118/1.4813966</DOI>\r\n    <ConferenceTitle>55th Annual Meeting
        and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM)</ConferenceTitle>\r\n
        \   <ConferenceStartDate>2013-08-04T00:00:00</ConferenceStartDate>\r\n    <ConferenceEndDate>2013-08-08T00:00:00</ConferenceEndDate>\r\n
        \   <ConferenceCity>INDIANAPOLIS</ConferenceCity>\r\n    <ConferenceStateCountry>IN</ConferenceStateCountry>\r\n
        \   <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>16</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS</CopyrightPublisher>\r\n
        \   <CopyrightCity>MELVILLE</CopyrightCity>\r\n    <PublicationImpactFactorList>2.83,2011,ClosestToPublicationYear|2.83,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>29/116;RADIOLOGY, NUCLEAR MEDICINE &amp;
        MEDICAL IMAGING;2011;SC;ClosestToPublicationYear|29/116;RADIOLOGY, NUCLEAR
        MEDICINE &amp; MEDICAL IMAGING;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>66016784</PublicationItemID>\r\n    <Title>Impact of
        race on early-stage lung cancer treatment and survival</Title>\r\n    <Abstract
        />\r\n    <AuthorList>Williams,Christina,D|Provenzale,Dawn,T|Stechuchak,Karen,M|Kelley,Michael,J</AuthorList>\r\n
        \   <AuthorCount>4</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Meeting
        Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference Proceeding
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000208943900230</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF CLINICAL ONCOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>30</Volume>\r\n    <Issue>34</Issue>\r\n    <Pagination />\r\n
        \   <PublicationDate>2012-12-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2012</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0732-183X</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\" />\r\n
        \   <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\" />\r\n
        \   <OrdinalRank>17</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\"
        />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>AMER SOC CLINICAL ONCOLOGY</CopyrightPublisher>\r\n
        \   <CopyrightCity>ALEXANDRIA</CopyrightCity>\r\n    <PublicationImpactFactorList>18.038,2012,ExactPublicationYear|18.038,2012,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>5/197;ONCOLOGY;2012;SC;ExactPublicationYear|5/197;ONCOLOGY;2012;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>VA</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>65972752</PublicationItemID>\r\n    <Title>WVU Cancer
        Center study focuses on promising new lung cancer treatment.</Title>\r\n    <Abstract
        />\r\n    <AuthorList />\r\n    <AuthorCount>0</AuthorCount>\r\n    <KeywordList
        />\r\n    <DocumentTypeList>Journal Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited xsi:nil=\"true\" />\r\n    <TimesNotSelfCited xsi:nil=\"true\"
        />\r\n    <PMID>24902470</PMID>\r\n    <PublicationSourceTitle>West Virginia
        medical journal</PublicationSourceTitle>\r\n    <Volume>110</Volume>\r\n    <Issue>2</Issue>\r\n
        \   <Pagination>49-?</Pagination>\r\n    <PublicationDate>2014-03-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2014</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>0043-3284</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\"
        />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\"
        />\r\n    <OrdinalRank>18</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\"
        />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher />\r\n    <CopyrightCity />\r\n    <CopyrightStateProvince
        />\r\n    <CopyrightCountry>UNITED STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>65924245</PublicationItemID>\r\n
        \   <Title>Relapsed small cell lung cancer: treatment options and latest developments</Title>\r\n
        \   <Abstract>According to recent analyses, there was a modest yet significant
        improvement in median survival time and 5-year survival rate of limited stage
        small cell lung cancer (SCLC) in North America, Europe, Japan and other countries
        over the last 30 years. The median survival time of limited stage SCLC is
        15-20 months and 5-year survival rate is 15% or less. In terms of extensive
        stage SCLC, a median survival time of 9.4-12.8 months and 2-year survival
        of 5.2-19.5% are still disappointing. Despite being highly sensitive to first-line
        chemotherapy and radiotherapy treatments, most patients with SCLC experience
        relapse within 2 years and die from systemic metastasis. While several clinical
        trials of cytotoxic chemotherapies and molecular targeting agents have been
        investigated in the treatment of relapsed SCLC, none showed a significant
        clinical activity to be able to exceed topotecan as second-line chemotherapy.
        There are problematic issues to address for relapsed SCLC, such as standardizing
        the treatment for third-line chemotherapy. Topotecan alone was the first approved
        therapy for second-line treatment for relapsed SCLC. Amrubicin is a promising
        drug and a variety of trials evaluating its efficacy have been carried out.
        Amrubicin has shown superiority to topotecan in a Japanese population, but
        was not superior in a study of western patients. There are some controversial
        issues for relapsed SCLC, such as treatment for older patients, third-line
        chemotherapy and efficacy of molecular targeting therapy. This article reviews
        current standard treatment, recent clinical trials and other topics on relapsed
        SCLC.</Abstract>\r\n    <AuthorList>Asai,Nobuhiro,|Ohkuni,Yoshihiro,|Kaneko,Norihiro,|Yamaguchi,Etsuro,|Kubo,Akihito,</AuthorList>\r\n
        \   <AuthorCount>5</AuthorCount>\r\n    <KeywordList>ACTIVE METABOLITE|COMBINATION
        CHEMOTHERAPY|PREVIOUSLY TREATED PATIENTS|ENDOTHELIAL GROWTH-FACTOR|PHASE-II
        TRIAL|ADOPTIVE IMMUNOTHERAPY|2ND-LINE CHEMOTHERAPY|FACTOR RECEPTOR MUTATIONS|INTRAVENOUS
        TOPOTECAN|3RD-LINE CHEMOTHERAPY|chemotherapy|small cell lung cancer|sensitive
        relapse|Refractory relapse</KeywordList>\r\n    <DocumentTypeList>Review</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>86</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>24587832</PMID>\r\n    <WoSItemID>000335816900004</WoSItemID>\r\n
        \   <PublicationSourceTitle>THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>6</Volume>\r\n    <Issue>2</Issue>\r\n    <Pagination>69-82</Pagination>\r\n
        \   <PublicationDate>2014-03-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2014</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1758-8340</ISSN>\r\n    <DOI>10.1177/1758834013517413</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>19</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>SAGE PUBLICATIONS
        LTD</CopyrightPublisher>\r\n    <CopyrightCity>LONDON</CopyrightCity>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED KINGDOM</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n</ArrayOfPublicationItem>"
    http_version: 
  recorded_at: Sat, 06 Dec 2014 02:06:44 GMT
recorded_with: VCR 2.5.0
